The scaffold’s design reflects a growing recognition in biomaterials science that tumor removal and tissue reconstruction have traditionally been treated as separate clinical challenges. Surgeons excise the tumor, then wait—sometimes through multiple additional interventions—for the bone defect to heal, all while monitoring for local recurrence. The new scaffold attempts to collapse this timeline by embedding three complementary therapeutic functions into a single printed structure. Each component was chosen for a specific biochemical role, and together they form what the researchers describe as a catalytic-immune system working in concert with osteoinductive signaling.

At the heart of the antitumor function is a dopamine–manganese coordination nanozyme, abbreviated DM, which forms a mussel-inspired catalytic coating on the scaffold surface. The mussel-inspired chemistry is significant because polydopamine coatings adhere robustly to diverse substrates under mild aqueous conditions, allowing the nanozyme to be integrated without harsh coupling reagents that could damage the delicate biological cargo carried elsewhere in the scaffold. Nanozymes—engineered nanomaterials that mimic the catalytic activity of natural enzymes—have attracted intense interest because they combine enzyme-like reactivity with the stability, tunability, and manufacturability of synthetic materials.

The DM nanozyme behaves differently depending on the chemical environment it encounters, which is the key to its dual function. In the acidic milieu characteristic of tumor tissue, it exhibits peroxidase-like activity, catalyzing Fenton-type reactions that generate highly reactive hydroxyl radicals. These radicals attack tumor cells directly, while the nanozyme simultaneously depletes glutathione, the antioxidant molecule that cancer cells rely on to neutralize oxidative stress. The combined effect overwhelms the tumor cells’ redox defenses and induces oxidative stress–mediated cell death. This chemodynamic strategy exploits a vulnerability that is specific to the tumor microenvironment, so the lethal chemistry is triggered where the acidity marks malignant tissue rather than throughout the body.

Under physiological pH, however, the same nanozyme switches roles entirely. In the neutral conditions of healthy regenerating tissue, DM displays superoxide dismutase-like and catalase-like activities, the two enzymatic steps that together convert destructive superoxide radicals into water and oxygen. In this mode, the nanozyme scavenges reactive oxygen species and helps maintain redox homeostasis. That matters for bone repair because excessive reactive oxygen species are known to impair osteoblast function and drive the chronic inflammation that stalls fracture healing. By quenching oxidative stress at the defect site, the coating creates a biochemical environment in which bone-forming cells can operate, effectively turning the tumor-killing catalyst into a tissue-protective antioxidant once the malignant chemistry has been neutralized.

The second therapeutic arm of the scaffold is immunological. Encapsulated within the hydrogel are dendritic cell-derived exosomes loaded with a cyclic dinucleotide that acts as an agonist of STING, the stimulator of interferon genes pathway. STING signaling is a central hub of innate immunity: when activated, it prompts cells to produce type I interferons and other inflammatory mediators that recruit and activate cytotoxic T lymphocytes capable of hunting down tumor cells. Dendritic cells are the professional antigen-presenting cells of the immune system, and exosomes derived from them offer a natural delivery vehicle that can ferry their immunostimulatory cargo to target cells while evading rapid clearance. The scaffold’s hydrogel matrix provides sustained release of these Dex-CDN particles, prolonging the local immune activation window rather than delivering a single transient dose.

This local immune strategy addresses one of the most persistent fears after bone-metastatic tumor surgery: microscopic disease left behind at the resection margin. Catalytic therapy kills cells it can reach directly, but the STING agonist is intended to do something different—convert the surgical site itself into an immunological alert zone where the patient’s own adaptive immune system is primed against residual tumor cells. Combining chemodynamic cell killing with immune checkpoint-free immune activation is an increasingly popular concept in oncology research, because dying tumor cells release antigens that, in the presence of interferon signaling, can be presented to T cells to generate a systemic antitumor response.

The third arm of the scaffold is dedicated to rebuilding bone. The researchers crosslinked the hydrogel network with methacrylated osteogenic growth peptide, or OGP-MA. Osteogenic growth peptide is a naturally occurring short peptide found in bone and blood that stimulates osteoblast proliferation and bone formation. By modifying it with methacrylate groups, the team made it copolymerizable into the GelMA network, so the osteogenic signal is not simply adsorbed onto the surface where it would diffuse away quickly, but is covalently incorporated into the scaffold architecture. According to the study, OGP-MA triggers osteogenic differentiation through the BMP/Smad signaling pathway, one of the canonical cascades that drives mesenchymal stem cells toward the bone-forming lineage.

The choice of a 3D-printed sodium alginate/GelMA hydrogel as the carrier is itself a technical decision with clinical implications. Alginate contributes mechanical robustness and printability, while GelMA—a gelatin derivative bearing methacrylate groups that crosslink under light—offers cell-adhesive motifs and controllable degradation. Printing the scaffold allows its internal architecture and pore structure to be tailored to the geometry of the specific bone defect, an advantage over prefabricated implants when reconstructing irregular post-resection cavities. The hydrogel’s hydrated, soft matrix is also compatible with the encapsulated exosomes and peptide, protecting the biological cargo while allowing gradual release as the material degrades.

The integrated design—catalytic tumor ablation, STING-driven immunity, and OGP-driven osteogenesis within one printed implant—offers what the authors present as a promising strategy for localized tumor control and bone regeneration following resection of bone-metastatic tumors. The work was supported by funding from China’s National Key Research and Development Program, the National Science and Technology Major Project, the National Natural Science Foundation of China, and several regional research programs, and the animal experiments were approved by the Dongguan People’s Hospital Laboratory Animal Welfare and Ethics Committee. While the platform will require extensive further validation before clinical use, it illustrates a broader shift in biomaterials engineering: implants conceived not as inert scaffolds that merely occupy space, but as programmable microenvironments that sense where they are, choose their chemistry accordingly, and orchestrate the body’s own defenses and repair mechanisms in the critical weeks after surgery.

Subject of Research: A 3D-printed hydrogel scaffold combining catalytic antitumor therapy, STING-mediated immunity, and osteogenic peptide signaling for bone repair after tumor resection

Article Title: A catalytic-immune OGP peptide-crosslinked 3D-printed hydrogel scaffold for concurrent antitumor therapy and bone regeneration

Article References: He, J., Wu, J., Wang, L., Yin, S., Yu, K., Liu, Y., Xu, D., Ji, T., Gao, Y., Du, Y., Gao, X., Cai, L., Xie, C., & Lu, X. (2026). A catalytic-immune OGP peptide-crosslinked 3D-printed hydrogel scaffold for concurrent antitumor therapy and bone regeneration. Advanced Composites and Hybrid Materials. https://doi.org/10.1007/s42114-026-02048-3

Image Credits: AI Generated

DOI: 10.1007/s42114-026-02048-3

Keywords: 3D-printed hydrogel scaffold, bone metastasis, nanozymes, Fenton reaction, STING agonist, dendritic cell exosomes, osteogenic growth peptide, bone regeneration, chemodynamic therapy, GelMA, tumor microenvironment, BMP/Smad signaling